New non-hormonal drug approved for managing menopause symptoms

The Central Drugs Standard Control Organisation (CDSCO) approved fezolinetant, a non-hormonal drug for menopausal hot flushes and night sweats. Doctors noted this approval marks an important development in menopause management. Clinical trials found that 58.7% of women taking the 45 mg dose experienced at least a 50% reduction in hot flush frequency by week 12. However, the drug carries a risk of elevated liver enzymes and, in rare cases, serious liver injury.